Drug Database
Back to search

Spain· ES:89988

DALBAVANCINA TEVA 500 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION EFG

A dalbavancin product containing dalbavancina, registered in Spain by Teva B.V.. The same ATC class is registered in 16 of our 19 countries.

ATC J01XA04

Checked against AEMPS CIMA (Spain) on

Informational only — not a medical device.

SOURCE REGISTER · ESAEMPS CIMA (Spain)normalisedDALBAVANCINA TEVA 500 MG POLVO PARA C…ATCJ01XA04REGISTER NO.ES:89988PACKS LISTED0CHECKEDJune 3, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about dalbavancinaAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Dalbavancin is registered in 16 of 19 countries.

Countries holding a registration under ATC J01XA04 (dalbavancin), each read from that country’s own register.

  • This record: Spain, from AEMPS CIMA (Spain)
  • 9 of them publish a price we can compare per daily dose
Search dalbavancin products by name

Dalbavancin · ATC J01XA04

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

AEMPS CIMA (Spain)
Active substance
dalbavancina
Manufacturer
Teva B.V.
Country
Spain (ES)
ATC code
J01XA04
ATC class
Dalbavancin
Defined daily dose
1.5 g, P
Reimbursed
Not published by this register
Source register
AEMPS CIMA (Spain)
Last checked
June 3, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

7 interactions on record for dalbavancin.

Graded by severity as the source publishes them — 7 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check dalbavancin against other medicinesHow interaction checks work

Dalbavancin · interactions on record

7 records

  • 7 moderate

Most severe, free to view

  • Sodium picosulfateA06AB08moderate
  • Levonorgestrel and ethinylestradiolG03AA07moderate
  • Desogestrel and ethinylestradiolG03AA09moderate
  • Drospirenone and ethinylestradiolG03AA12moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Dalbavancin in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All dalbavancin products

Authorised across Europe · EMA

The same active substance is authorised in 16 EEA countries. Names it is sold under:

  • Austria · Dalbavancin, Dalbavancin Accord
  • Germany · Dalbavancin Accord, Dalbavancin Baxter
  • Denmark · Dalbavancin Adalvo, Dalbavancin Teva
  • Finland · Dalbavancin Adalvo, Dalbavancin Tillomed
  • France · Dalbavancine Accord, Dalbavancine Reddy Pharma
  • United Kingdom (Northern Ireland) · Dalbavancin Accord, Dalbavancin Reig Jofre Uk
  • Greece · Bavalda, Dalbavancin Accord
  • Iceland · Xydalba
  • Italy · Dalbavancina Accord, Dalbavancina Dr. Reddy’s
  • Liechtenstein · Xydalba
  • Malta · Bavalda, Dalbavancin Adalvo
  • Norway · Dalbavancin Tillomed, Xydalba
  • Poland · Dalbavancin Accord, Dalbavancin Reig Jofre
  • Portugal · Dalbavancina Anfarm
  • Sweden · Dalbavancin Accord, Dalbavancin Bioglan
  • Slovakia · Dalbavancin Adalvo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/05ce84a1-2a1c-4327-8f4b-7754c95d6401
GET /v1/drugs/05ce84a1-2a1c-4327-8f4b-7754c95d6401?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cpresc": "Uso Hospitalario",
  "estado": "{\"aut\":1753785965000}",
  "nregistro": "89988",
  "substance": "dalbavancina"
}
API referenceMCP serverPlans

See everything about dalbavancin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console